Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c in HER2-expressing Advanced Ovarian Cancer
NCT04828616Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of DP303c in ovarian cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
DP303c
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04828616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828616.